Over the last few months, Johnson & Johnson has made sweeping moves to resolve a mountain of litigation involving the safety and marketing of its opioid and talc products. Friday brought word of a lower-profile resolution, as J&J revealed it has settled liability claims surrounding its antipsychotic drug Risperdal.

The U.S. Supreme Court rejected a bid by Johnson & Johnson (JNJ.N) to overturn a $70 million jury verdict against the pharmaceutical company for its failure to warn about risks associated with off-label uses of its antipsychotic drug Risperdal.

Healthcare giant Johnson & Johnson (NYSE: JNJ) got good news on Friday when a Philadelphia judge drastically reduced the $8 billion punitive damage verdict the company was initially ordered to pay in October down to just $6.8 million.

Johnson & Johnson (NYSE: JNJ) has long been plagued with lawsuits alleging its talcum products contain the cancer-causing substance asbestos. Unluckily for Johnson & Johnson, these allegations are a series in a long line of legal troubles. Just in October 2019, Johnson & Johnson was directed to pay $8 billion in damages to plaintiffs for pressuring medical providers to prescribe Risperdal to patients.

Johnson & Johnson has faced numerous negative headlines on its talc and opioid litigation in recent months, but at the same time, lawsuits over its antipsychotic Risperdal present another set of challenges. And lately, they're not going the company's way.

Johnson & Johnson faces lawsuits over opioids, talc, medical devices—and now, thousands more featuring the antipsychotic drug Risperdal. Pennsylvania's Supreme Court on Wednesday revived a raft of previously tossed-out claims alleging the drug caused males to develop breasts.

Johnson & Johnson (NYSE: JNJ) is a massive medical products conglomerate. But skimming through the headlines it's been producing lately, you'd almost think it was a law firm -- a really bad law firm, that loses a lot of cases:

In a statement issued last night, J&J said the verdict is “grossly disproportionate with the initial compensatory award” in the case and is confident that it will be overturned in the appeals process. The company added that the $8 billion verdict is inconsistent with other Risperdal lawsuits outside of Philadelphia. J&J said it will begin the process to set aside the verdict.

A Philadelphia jury on Tuesday said that Johnson & Johnson must pay $8 billion in punitive damages to a man who says a drug manufactured by the company caused him to grow breasts.